Patni becomes chief of R&D at Reata

Reata Pharmaceuticals Inc. (NASDAQ:RETA) hired Rajiv Patni as EVP and chief R&D officer. Patni previously served as CMO at Global Blood Therapeutics Inc., Portola Pharmaceuticals Inc. and Adamas Pharmaceuticals Inc. Reata’s Skyclarys omaveloxolone was granted FDA approval in February to treat Friedreich’s ataxia.

Brain and aging disorders company Damona Pharmaceuticals Inc. named John Reilly as CEO and board member. Reilly was president and CEO of Apic Bio Inc., a gene therapy company he co-founded. ...